Core Viewpoint - Nanjing New Pharmaceutical announced the resignation of General Manager Zhang Shixi due to work adjustments and appointed Chen Jianxu as the new General Manager effective immediately following the board's approval [1] Group 1 - Zhang Shixi submitted a written resignation report to the board of directors [1] - The second meeting of the second board of directors was held on February 11, 2026, to discuss the appointment of a new General Manager [1] - Chen Jianxu's term as General Manager will last until the end of the current board's term [1]

Core Viewpoint - Nanjing Pharmaceutical (688189) plans to transfer part of its subsidiary's accounts receivable through a public listing to optimize its asset structure and improve asset liquidity and safety [1] Group 1: Asset Transfer Details - The company intends to transfer accounts receivable with a total book balance of 48,978.4 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 45,979.45 million yuan, resulting in a net book value of 2,998.95 million yuan for the receivables being transferred [1] Group 2: Strategic Objectives - The asset transfer aims to reduce accounts receivable management costs and enhance the quality of asset operations [1] - This move is expected to support better operational development for the company and protect the legal rights of all shareholders [1]

Core Viewpoint - The company, Hunan Nanxin Pharmaceutical Co., Ltd., is planning to transfer part of its accounts receivable through public listing to optimize its asset structure, focus on core business, and enhance risk resistance [1][2]. Group 1: Strategic Initiatives - The public listing of accounts receivable aims to reduce management costs associated with receivables, allowing the company to concentrate resources on core development areas and increase investment in innovative drug research [1]. - This initiative is expected to improve the company's asset structure and operational quality by converting stagnant receivables into cash, thereby reducing the proportion of accounts receivable in total assets and transferring credit risk [1]. Group 2: Financial Implications - The transfer of accounts receivable is anticipated to enhance liquidity and security of funds, providing a quick influx of cash to alleviate pressure from capital occupation and mitigate cash flow issues caused by delayed payments [2]. - The company plans to continue optimizing its accounts receivable management system and strengthen its focus on core business and research innovation to create higher value for investors and contribute to industry development [2].

证券代码：688189 证券简称：南新制药 公告编号：2026-008 湖南南新制药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 11 日 （二） 股东会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制药 有限公司 313 会议室 本次股东会由湖南南新制药股份有限公司（以下简称"公司"）董事会召集， 由董事长张世喜先生主持，会议采用现场投票与网络投票相结合的表决方式进行 | 1、出席会议的股东和代理人人数 | 87 | | --- | --- | | 普通股股东人数 | 87 | | 2、出席会议的股东所持有的表决权数量 | 79,509,579 | | 普通股股东所持有表决权数量 | 79,509,579 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 29.3481 | | 普通股股东所持有表决权数量占公司表决权 ...

Core Viewpoint - Nanxin Pharmaceutical (688189.SH) announced the resignation of its General Manager, Zhang Shixi, due to work adjustments, effective immediately upon delivery of the resignation report to the board [1] Group 1: Management Changes - Zhang Shixi will continue to serve as a director, chairman, and the convener of the board's strategic committee after resigning as General Manager [1] - The company held its 22nd meeting of the second board of directors on February 11, 2026, where it approved the appointment of Chen Jianxu as the new General Manager [1] - Chen Jianxu's term as General Manager will last until the end of the current board's term [1]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) aims to optimize its asset structure and improve the quality of asset operations by transferring part of its accounts receivable through a public listing [1] Group 1: Asset Transfer Details - The company plans to transfer accounts receivable with a total book balance of 489.784 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 459.7945 million yuan, resulting in a book value of 29.9895 million yuan for the receivables being transferred [1] - The asset transfer is expected to enhance the company's operational development and protect the legal rights of the company and all shareholders [1] Group 2: Transaction Process - The transaction will be conducted through a public listing, and no transaction agreement has been signed yet [1] - It is currently unclear whether the transaction will constitute a related party transaction [1] - If the determined buyer through the public listing process is a related party, the company will follow the necessary review procedures for related party transactions [1]

证券代码：688189 证券简称：南新制药 公告编号：2026-009 湖南南新制药股份有限公司 关于聘任总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南南新制药股份有限公司（以下简称"公司"）董事会于近日收到张世喜 先生提交的书面辞职报告，张世喜先生因工作调整原因申请辞去公司总经理职务。 根据《公司法》《公司章程》的有关规定，张世喜先生的辞职报告自送达董事会 之日起生效。辞职后，张世喜先生仍担任公司董事、董事长、董事会战略委员会 召集人职务。 相关规定做好交接工作。截至本公告披露日，张世喜先生不存在未履行完毕的公 开承诺。 公司及公司董事会对张世喜先生在任职期间为公司发展作出的贡献表示衷 心感谢！ 二、高级管理人员聘任情况 根据《公司法》《中华人民共和国证券法》《上海证券交易所科创板上市公司 自律监管指引 1 号——规范运作》等法律法规、规范性文件及《公司章程》等有 关规定，经公司第二届董事会提名委员会进行任职资格审查后，公司于 2026 年 2 月 11 日召开第二届董事会第二十二次会 ...

证券代码：688189 证券简称：南新制药 公告编号：2026-010 湖南南新制药股份有限公司 关于拟公开挂牌转让部分应收账款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、本次交易概况 为优化公司资产结构，进一步降低应收账款管理成本，提高资产运营质量， 提升资产流动性及保障资金安全，公司拟通过公开挂牌方式转让子公司部分应收 账款，截至评估基准日 2025 年 9 月 30 日，本次拟转让的应收账款账面余额合计 48,978.40 万元，已计提坏账准备 45,979.45 万元，账面价值 2,998.95 万元。 湖南南新制药股份有限公司（以下简称"公司"）拟将其子公司持有的部 分应收账款（以下简称"标的资产"）以公开挂牌的形式在湖南省联合产权交易 所有限公司（以下简称"湖南联交所"）进行转让。本次公开挂牌转让价格以评 估值为参考依据，最终交易金额以实际成交价格为准。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重 组。 本次公开挂牌转让部分应收账款事项已经公司第二届董事会战略 ...

北京大成(广州) 律师事务所 关于湖南南新制药股份有限公司 2026 年第一次临时股东会的 大成 DENTONS 法律意见书 大成 is Dentons' Preferred Law Firm in China. guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 北京大成(广州)律师事务所 关于湖南南新制药股份有限公司 2026年第一次临时股东会法律意见书 致: 湖南南新制药股份有限公司 2026 年 1 月 26 日 , 公司董事会在第二届董事会第二十一次会议上审议通过 了《关于提请召开 2026 年第一次临时股东会的议案》，决定于 2026 年 2 月 11 日召开 2026年第一次临时股东会。 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 ...

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) announced the resignation of General Manager Zhang Shixi due to work adjustments, effective immediately upon delivery of the resignation report to the board [1] Group 1: Management Changes - Zhang Shixi will continue to serve as a director, chairman, and convener of the board's strategic committee after resigning as General Manager [1] - The company appointed Chen Jianxu as the new General Manager, with the term lasting until the end of the current board's tenure [1]